Page 81 - 2019_05-HaematologicaMondo-web

Complement is involved in sickle red cell adhesion
hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121(8): 1276-1284.
9. Hebbel RP. Adhesion of sickle red cells to endothelium: myths and future directions. Transfus Clin Biol. 2008;15(1-2):14-18.
10. Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell dis- ease. Blood. 2016;127(7):810-819.
11. Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythro- cytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113(17):4094-4100.
12. Risitano AM, Notaro R, Pascariello C, et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from comple- ment-mediated hemolysis and C3 fragment. Blood. 2012;119(26):6307-6316.
13. Frimat M, Tabarin F, Dimitrov JD, et al. Complement activation by heme as a sec- ondary hit for atypical hemolytic uremic syndrome. Blood. 2013;122(2):282-292.
14. Roumenina LT, Loirat C, Dragon-Durey MA, et al. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365(1-2):8-26.
15. Test ST, Woolworth VS. Defective regula- tion of complement by the sickle erythro- cyte: evidence for a defect in control of membrane attack complex formation. Blood. 1994;83(3):842-852.
16. Chudwin DS, Papierniak C, Lint TF, Korenblit AD. Activation of the alternative complement pathway by red blood cells from patients with sickle cell disease. Clin Immunol Immunopathol. 1994;71(2):199- 202.
17. Wang RH, Phillips G Jr, Medof ME, Mold C. Activation of the alternative complement pathway by exposure of phos- phatidylethanolamine and phosphatidylser- ine on erythrocytes from sickle cell disease patients. J Clin Invest. 1993;92(3):1326-1335.
18. Mold C, Tamerius JD, Phillips G Jr. Complement activation during painful crisis in sickle cell anemia. Clin Immunol Immunopathol. 1995;76(3 Pt 1):314-320.
19. Gavriilaki E, Mainou M, Christodoulou I, et al. In vitro evidence of complement activa- tion in patients with sickle cell disease. Haematologica. 2017;102(12):e481-e482.
20. Koethe SM, Casper JT, Rodey GE. Alternative complement pathway activity in sera from patients with sickle cell disease. Clin Exp Immunol. 1976;23(1):56-60.
21. Strauss RG, Asbrock T, Forristal J, West CD. Alternative pathway of complement in sick- le cell disease. Pediatr Res. 1977;11(4):285- 289.
22. de Ciutiis A, Polley MJ, Metakis LJ, Peterson CM. Immunologic defect of the alternate pathway-of-complement activation post- splenectomy: a possible relation between splenectomy and infection. J Natl Med Assoc. 1978;70(9):667-670.
23. Schaid TR, Nguyen J, Chen C, et al. Complement activation in a murine model of sickle cell disease: inhibition of vaso- occlusion by blocking C5 activation. Blood. 2016;128(22):158.
24. Merle NS, Grunenwald A, Rajaratnam H, et al. Intravascular hemolysis activates comple- ment via cell-free heme and heme-loaded microvesicles. JCI Insight. 2018;3(12).
25. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol.
2009;9(10):729-740.
26. de Cordoba SR, de Jorge EG. Translational
mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol. 2008;151(1):1-13.
27. Kajander T, Lehtinen MJ, Hyvarinen S, et al. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost dis- crimination by complement. Proc Natl Acad Sci U S A. 2011;108(7):2897-2902.
28. Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offen- sive. Nat Rev Nephrol. 2016;12(7):383-401.
29. Wu J, Wu YQ, Ricklin D, et al. Structure of complement fragment C3b-factor H and implications for host protection by comple- ment regulators. Nat Immunol. 2009;10(7): 728-733.
30. Morgan HP, Schmidt CQ, Guariento M, et al. Structural basis for engagement by com- plement factor H of C3b on a self surface. Nat Struct Mol Biol. 2011;18(4):463-470.
31. Dworkis DA, Klings ES, Solovieff N, et al. Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1. Am J Hematol. 2011;86(2):220- 223.
32. Magro CM, Momtahen S, Mulvey JJ, et al. Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome. Am J Dermatopathol. 2015;37(5):349-356; quiz 357-349.
33. Scambi C, Ugolini S, Jokiranta TS, et al. The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study. PLoS One. 2015;10(2):e0114856.
34. Vianello A, Vencato E, Cantini M, et al. Improvement of maternal and fetal out- comes in women with sickle cell disease treated with early prophylactic erythrocyta- pheresis. Transfusion. 2018;58(9):2192- 2201.
35. de Jong K, Emerson RK, Butler J, et al. Short survival of phosphatidylserine-exposing red blood cells in murine sickle cell anemia. Blood. 2001;98(5):1577-1584.
36. de Jong K, Larkin SK, Styles LA, Bookchin RM, Kuypers FA. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood. 2001;98(3):860-867.
37. de Franceschi L, Turrini F, Honczarenko M, et al. In vivo reduction of erythrocyte oxi- dant stress in a murine model of beta-tha- lassemia. Haematologica. 2004;89(11):1287- 1298.
38. Hebbel RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest. 1997;100(11 Suppl):S83-86.
al. Factors associated with survival in a con- temporary adult sickle cell disease cohort. Am J Hematol. 2014;89(5):530-535.
44. Kalambur VS, Mahaseth H, Bischof JC, et al. Microvascular blood flow and stasis in trans- genic sickle mice: utility of a dorsal skin fold chamber for intravital microscopy. Am J Hematol. 2004;77(2):117-125.
45. Vercellotti GM, Zhang P, Nguyen J, et al. Hepatic overexpression of hemopexin inhibits inflammation and vascular stasis in murine models of sickle cell disease. Mol Med. 2016;22.
46. Serjeant GR. Leg ulceration in sickle cell ane- mia. Arch Intern Med. 1974;133(4):690-694. 47. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA.
2014;312(10):1033-1048.
48. Matsui NM, Borsig L, Rosen SD, et al. P-
selectin mediates the adhesion of sickle ery- throcytes to the endothelium. Blood. 2001;98(6):1955-1962.
49. Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013;122(24):3892-3898.
50. Wood K, Russell J, Hebbel RP, Granger DN. Differential expression of E- and P-selectin in the microvasculature of sickle cell trans- genic mice. Microcirculation. 2004;11(4): 377-385.
51. Hidalgo A, Chang J, Jang JE, et al. Heterotypic interactions enabled by polar- ized neutrophil microdomains mediate thromboinflammatory injury. Nat Med. 2009;15(4):384-391.
52. Ataga KI, Kutlar A, Kanter J. Crizanlizumab in sickle cell disease. N Engl J Med. 2017;376(18):1796.
53. Cherqui S, Kurian SM, Schussler O, et al. Isolation and angiogenesis by endothelial progenitors in the fetal liver. Stem Cells. 2006;24(1):44-54.
54. Aranguren XL, Agirre X, Beerens M, et al. Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature. Blood. 2013;122(24):3982-3992.
55. Lotzer K, Dopping S, Connert S, et al. Mouse aorta smooth muscle cells differenti- ate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor- 1/lymphotoxin beta-receptor NF-kappaB signaling. Arterioscler Thromb Vasc Biol. 2010;30(3):395-402.
56. Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the comple- ment system. J Exp Med. 2005;201(6):871-
39. Montes RA, Eckman JR, Hsu LL, Wick TM.
Sickle erythrocyte adherence to endotheli- 879.
um at low shear: role of shear stress in prop- agation of vaso-occlusion. Am J Hematol. 2002;70(3):216-227.
40. Barabino GA, McIntire LV, Eskin SG, Sears DA, Udden M. Endothelial cell interactions with sickle cell, sickle trait, mechanically injured, and normal erythrocytes under con- trolled flow. Blood. 1987;70(1):152-157.
41. Jokiranta TS, Hellwage J, Koistinen V, Zipfel PF, Meri S. Each of the three binding sites on complement factor H interacts with a dis- tinct site on C3b. J Biol Chem. 2000;275(36):27657-27662.
42. Matte A, De Falco L, Federti E, et al. Peroxiredoxin-2: a novel regulator of iron homeostasis in ineffective erythropoiesis. Antioxid Redox Signal. 2018;28(1):1-14.
43. Elmariah H, Garrett ME, De Castro LM, et
57. Chen G, Chang J, Zhang D, et al. Targeting Mac-1-mediated leukocyte-RBC interac- tions uncouples the benefits for acute vaso- occlusion and chronic organ damage. Exp Hematol. 2016;44(10):940-946.
58. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615-624.
59. Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD. Complement component C3 - the "Swiss Army Knife" of innate immunity and host defense. Immunol Rev. 2016;274(1):33-58.
60. Beller DI, Springer TA, Schreiber RD. Anti- Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med. 1982;156(4):1000-1009.
haematologica | 2019; 104(5)
927